Format

Send to

Choose Destination
Int J Mol Sci. 2014 Jul 31;15(8):13437-60. doi: 10.3390/ijms150813437.

Hip osteoarthritis in dogs: a randomized study using mesenchymal stem cells from adipose tissue and plasma rich in growth factors.

Author information

1
Department of Animal Medicine and Surgery, CEU Cardenal Herrera University, C/Tirant lo Blanc, 7, 46115 Alfara del Patriarca, Valencia, Spain. belen.cuervo@uch.ceu.es.
2
Department of Animal Medicine and Surgery, CEU Cardenal Herrera University, C/Tirant lo Blanc, 7, 46115 Alfara del Patriarca, Valencia, Spain. ramon.cugat@sportrauma.com.
3
Department of Animal Medicine and Surgery, University of Cordoba, 14071 Cordoba, Spain. pv2dopej@uco.es.
4
Department of Animal Medicine and Surgery, University of Las Palmas de Gran Canaria, 35413 Las Palmas de Gran Canaria, Spain. jvilar@dpat.ulpgc.es.
5
Department of Animal Medicine and Surgery, University of Las Palmas de Gran Canaria, 35413 Las Palmas de Gran Canaria, Spain. mmorales@dpat.ulpgc.es.
6
Garcia Cugat Foundation CEU UCH Chair of Medicine and Regenerative Surgery, 08006 Barcelona, Spain. ramon.cugat@sportrauma.com.

Abstract

PURPOSE:

The aim of this study was to compare the efficacy and safety of a single intra-articular injection of adipose mesenchymal stem cells (aMSCs) versus plasma rich in growth factors (PRGF) as a treatment for reducing symptoms in dogs with hip osteoarthritis (OA).

METHODS:

This was a randomized, multicenter, blinded, parallel group. Thirty-nine dogs with symptomatic hip OA were assigned to one of the two groups, to receive aMSCs or PRGF. The primary outcome measures were pain and function subscales, including radiologic assessment, functional limitation and joint mobility. The secondary outcome measures were owners' satisfaction questionnaire, rescue analgesic requirement and overall safety. Data was collected at baseline, then, 1, 3 and 6 months post-treatment.

RESULTS:

OA degree did not vary within groups. Functional limitation, range of motion (ROM), owner's and veterinary investigator visual analogue scale (VAS), and patient's quality of life improved from the first month up to six months. The aMSCs group obtained better results at 6 months. There were no adverse effects during the study. Our findings show that aMSCs and PRGF are safe and effective in the functional analysis at 1, 3 and 6 months; provide a significant improvement, reducing dog's pain, and improving physical function. With respect to basal levels for every parameter in patients with hip OA, aMSCs showed better results at 6 months.

PMID:
25089877
PMCID:
PMC4159804
DOI:
10.3390/ijms150813437
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center